Efficacy and safety of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure

Efficacy and safety of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure - Tolvaptan in CKD Stage 4-5 with CHF

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029787

Enrollment

Registered

2017-11-01

Start date

2018-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe chronic kidney disease complicated by congestive heart failure

Interventions

tolvaptan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) A patient who has an insufficient fluid retention symptom with an existing diuretic (eg furosemide). 2) CKD stage 4-5

Exclusion criteria

Exclusion criteria: 1) Hemodynamics are unstable 2) Hypersensitivity to tolvaptan 3) Anuria 4) Can not feel dry mouth or can not drink water 5) Hypernatremia 6) Pregnant 7) Already prescribed tolvaptan 8) Patient judged inappropriate by the examining physician

Design outcomes

Primary

Measure	Time frame
Change rate to eGFR <6 (mL / min / 1.73 m2)	—

Countries

Japan

Contacts

Public ContactYukinao Sakai

Nippon Medical School Department of Nephrology

y-sakai@nms.ac.jp03-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026